Dapagliflozin Efficacious, Safe in Type 2 Diabetes Regardless of Pre-Treatment Systolic BP

SGLT2 inhibitors like dapagliflozin reduce hospitalization for heart failure and progression of diabetic nephropathy in patients with type 2 diabetes, but decrease systolic and diastolic blood pressure only minimally. Brigham researchers investigated whether their efficacy might depend on pre-treatment blood pressure.
Read More...